FDA spells out how the Covid-19 vari­ants im­pact the ef­fec­tive­ness of Re­gen­eron, Eli Lil­ly mAb treat­ments

The FDA on Thurs­day af­ter­noon up­dat­ed its three fact sheets on the mon­o­clon­al an­ti­body treat­ments from Eli Lil­ly and Re­gen­eron, of­fer­ing new da­ta on the sus­cep­ti­bil­i­ty of the SARS-CoV-2 vari­ants orig­i­nat­ing in the UK, Brazil, South Africa, Cal­i­for­nia and New York to each of the mAb ther­a­pies.

“Some vari­ants can cause re­sis­tance to one or more of the mAb ther­a­pies au­tho­rized to treat COVID-19,” FDA said. “Health care providers should re­view the au­tho­rized fact sheets for in­for­ma­tion on the use of the au­tho­rized mAb ther­a­pies against cur­rent­ly cir­cu­lat­ing vi­ral vari­ants.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER